Ku, Zhiqiang http://orcid.org/0000-0001-8347-0013
Xie, Xuping http://orcid.org/0000-0003-0918-016X
Hinton, Paul R. http://orcid.org/0000-0002-9554-4144
Liu, Xinli
Ye, Xiaohua
Muruato, Antonio E.
Ng, Dean C.
Biswas, Sujit
Zou, Jing
Liu, Yang
Pandya, Deepal
Menachery, Vineet D. http://orcid.org/0000-0001-8803-7606
Rahman, Sachi
Cao, Yu-An
Deng, Hui
Xiong, Wei
Carlin, Kevin B.
Liu, Junquan
Su, Hang
Haanes, Elizabeth J.
Keyt, Bruce A. http://orcid.org/0000-0002-3508-9223
Zhang, Ningyan http://orcid.org/0000-0002-4348-2180
Carroll, Stephen F. http://orcid.org/0000-0001-7366-9918
Shi, Pei-Yong http://orcid.org/0000-0001-5553-1616
An, Zhiqiang http://orcid.org/0000-0001-9309-2335
Article History
Received: 23 February 2021
Accepted: 26 May 2021
First Online: 3 June 2021
Competing interests
: The University of Texas System has filed a patent on the SARS-CoV-2 antibodies and the reverse genetic system and reporter SARS-CoV-2. The University of Texas System and IGM Biosciences have filed a joint patent on the SARS-CoV-2 IgM antibodies. The antibodies are being developed by IGM Biosciences for prophylactic and therapeutic treatment of COVID-19. P.R.H., D.C.N., D.P., S.R., Y-A.C., K.B.C., E.J.H., B.A.K. and S.F.C. are employees of IGM Biosciences. The other authors declare no competing interests.
Free to read: This content has been made available to all.